Product image of Liladros (Drospirenone, Ethinylestradiol) supplied by GNH India

Liladros

Active Ingredient:
Drospirenone, Ethinylestradiol
Origin:
EU

Liladros (Drospirenone, Ethinylestradiol)

Drospirenone/Ethinylestradiol, the active ingredient in Liladros, is a combined oral contraceptive presented as a tablet for oral use. It effectively prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH India supplies Liladros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is authorized in the European Union and meets international quality standards, providing reliable access to this hormonal contraceptive for qualified prescribers. GNH India also ensures consistent supply chains and regulatory compliance for global distribution.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Liladros, a combined oral contraceptive, is used to prevent pregnancy by suppressing ovulation and modifying cervical mucus.

  • Pregnancy prevention: prevents conception when taken as directed.
  • Contraception: provides reliable birth control for women of reproductive age.
  • Menstrual cycle regulation: can help achieve more predictable menstrual bleeding patterns.

How It Works

  • Drospirenone acts as a progestogenic agent with anti‑mineralocorticoid and anti‑androgenic activity, while ethinylestradiol provides estrogenic effects. Together they suppress the hypothalamic‑pituitary‑gonadal axis, reducing luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion, thereby inhibiting ovulation. They also thicken cervical mucus and induce endometrial changes that diminish the likelihood of implantation.

Side Effects

Liladros may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of the breasts.
  • Headache: occasional mild to moderate pain.
  • Weight gain: modest increase in body weight.
  • Mood changes: fluctuations in emotional state.
  • Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Arterial thrombosis: clot formation in arteries, potentially causing stroke or heart attack.
  • Hypertension: elevated blood pressure.
  • Liver disorders: jaundice or hepatic dysfunction.
  • Gallbladder disease: gallstones or cholecystitis.
  • Severe allergic reaction: anaphylaxis or angioedema.

Precautions & Warnings

Before prescribing Liladros, clinicians should consider several safety factors.

  • Assess cardiovascular risk: evaluate history of thromboembolic events before prescribing.
  • Screen for smoking status: avoid use in women over 35 who smoke.
  • Consider liver function: use cautiously in hepatic impairment.
  • Monitor blood pressure: combined estrogen‑progestin can raise blood pressure.
  • Avoid use during pregnancy: contraindicated (Category X).
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Liladros can interact with other medicines, requiring attention to potential changes in effectiveness or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive efficacy.
  • Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and increase bleeding risk.
  • Certain antiretrovirals (e.g., efavirenz): may lower hormone levels and compromise contraception.

Moderate Interactions (Monitor Closely)

  • SSRIs: may increase risk of mood‑related side effects.
  • Antihypertensives: combined pill may reduce blood‑pressure‑lowering effect.
  • Herbal supplements (e.g., St. John’s wort): may decrease contraceptive effectiveness.

Frequently Asked Questions

Liladros is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It works by inhibiting ovulation and altering cervical mucus, providing reliable birth control when taken as prescribed.

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while ethinylestradiol supplies estrogenic activity. Together they suppress the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation, thickening cervical mucus, and creating an endometrial environment that reduces the chance of implantation.

The dosing regimen for Liladros is determined by the prescribing healthcare professional. Typically, the product is taken once daily for a defined cycle, but the exact schedule, including any placebo days, must follow the prescriber’s instructions and the product label.

Liladros is contraindicated in pregnancy (Category X) and should not be used by women who are pregnant. Use during breastfeeding is generally not recommended unless the benefits outweigh the risks; clinicians should discuss individual circumstances with the patient.

To order Liladros, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Liladros contains drospirenone, a progestin with anti‑mineralocorticoid properties that may reduce water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while its side‑effect profile may differ slightly, especially regarding weight and blood‑pressure effects.

Liladros tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label.

Liladros is taken orally as a tablet, usually at the same time each day. It can be taken with or without food, but consistent daily timing helps maintain steady hormone levels and maximizes contraceptive effectiveness.

Serious risks include venous thromboembolism, arterial thrombosis, hypertension, severe liver disorders, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like unexplained leg pain, chest pain, severe headache, visual changes, or signs of an allergic reaction.

Liladros should not be used by women who are pregnant, have a history of thromboembolic disorders, smoke heavily and are over 35 years old, have uncontrolled hypertension, severe liver disease, known hypersensitivity to any component, or who are breastfeeding without medical guidance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT